Wedbush Issues Pessimistic Estimate for argenex Earnings

argenex SE (NASDAQ:ARGX - Free Report) - Wedbush decreased their Q2 2025 earnings estimates for argenex in a research note issued to investors on Monday, July 21st. Wedbush analyst D. Nierengarten now anticipates that the company will earn $3.41 per share for the quarter, down from their previous forecast of $3.43. Wedbush has a "Outperform" rating and a $715.00 price target on the stock. The consensus estimate for argenex's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex's Q3 2025 earnings at $4.22 EPS.

argenex (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenex had a net margin of 40.20% and a return on equity of 16.15%.

ARGX has been the topic of several other reports. Deutsche Bank Aktiengesellschaft upgraded shares of argenex from a "hold" rating to a "buy" rating in a report on Tuesday, July 8th. Robert W. Baird upgraded shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price objective on the stock in a report on Tuesday, May 13th. HC Wainwright restated a "buy" rating and set a $720.00 price objective on shares of argenex in a report on Tuesday, July 1st. Baird R W upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, Oppenheimer raised their price objective on shares of argenex from $704.00 to $708.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Nineteen equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $728.06.

argenex Price Performance

ARGX traded up $0.25 during mid-day trading on Wednesday, hitting $591.99. The stock had a trading volume of 487,813 shares, compared to its average volume of 364,772. The stock's fifty day simple moving average is $566.05 and its 200-day simple moving average is $598.66. The firm has a market capitalization of $36.23 billion, a price-to-earnings ratio of 36.52, a price-to-earnings-growth ratio of 1.00 and a beta of 0.37. argenex has a 1-year low of $473.67 and a 1-year high of $678.21.

Institutional Trading of argenex

Institutional investors have recently bought and sold shares of the business. GeoWealth Management LLC raised its position in shares of argenex by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after buying an additional 18 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after buying an additional 22 shares in the last quarter. WPG Advisers LLC acquired a new position in shares of argenex in the 1st quarter valued at approximately $37,000. FIL Ltd acquired a new position in shares of argenex in the 4th quarter valued at approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of argenex in the 4th quarter valued at approximately $38,000. Institutional investors own 60.32% of the company's stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.